Clinical Trials Logo

Filter by:
NCT ID: NCT04952987 Recruiting - Dry Eye Clinical Trials

Dry Eye Management With 3% Diquafosol Before and After Cataract Surgery

Start date: January 1, 2021
Phase:
Study type: Observational

The objective of this study is to evaluate the efficacy of Diquafosol 3% in the management of dry eyes before and after cataract surgery. Patients with pre-existing dry eyes and planned for cataract surgery will be started on Diquafosol eyedrops prior to surgery and treatment will be continued after cataract surgery. Eligible patients will undergo evaluation of dry eye at baseline and subsequently started on treatment with Diquafosol for the duration of 4 weeks before surgery. Further evaluations will be conducted on the day of surgery and at designated time points during and up to 12 weeks after surgery.

NCT ID: NCT04949256 Recruiting - Clinical trials for Metastatic Esophageal Squamous Cell Carcinoma

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Start date: July 28, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

NCT ID: NCT04936308 Recruiting - Clinical trials for Arthritis, Psoriatic

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

SOLSTICE
Start date: September 28, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.

NCT ID: NCT04932668 Recruiting - Clinical trials for Spasticity as Sequela of Stroke

Home Based Electrical Stimulation on Post-stroke Lower Limb Tightness.

Start date: November 5, 2020
Phase: N/A
Study type: Interventional

Spasticity is a common complication post stroke. Post-stroke spasticity along with weakness and lack of coordination result in gait abnormalities and functional limitations. Recent treatment option include neuromuscular electric stimulation (NMES), a form of therapy that applies electrical currents to produce contraction of innervated muscle by depolarizing local motor nerves. Currently, there are wide varieties of NMES devices available commercially for consumer. The main purpose of this study is to evaluate the feasibility and acceptability of a home-based NMES program on lower limb spasticity in patient with post-stroke more than 6 months and to assess the impact of the program. This is single arm prospective intervention study. Patient will apply home-based NMES on their leg for 20 minutes, 5 days a week for 4 weeks. At the end of the study, an outcome measures will be assessed and patient will be required to answer a questionnaires on their experience.

NCT ID: NCT04931940 Recruiting - Critical Illness Clinical Trials

The EFFORT Trial and EFFORT Outcomes Sub-study (EFFORT-Outcomes)

Start date: December 1, 2019
Phase: N/A
Study type: Interventional

The investigators will evaluate the effects of higher protein/amino acid dosing (≥2.2 g/kg/d) vs usual care of protein/amino acid dosing (≤1.2 g/kg/d) over muscle mass in nutritionally high risk ill patients

NCT ID: NCT04929821 Recruiting - Biliary Obstruction Clinical Trials

UNITY-B A Prospective, Multicentric, Single-arm Study to Evaluate the Safety and Efficacy of the UNITY-B Biodegradable Balloon-Expandable Biliary Stent System in Subjects With Biliary Strictures

Start date: October 16, 2017
Phase: N/A
Study type: Interventional

STUDY TYPE: Feasibility study STUDY DESIGN: Prospective, multicenter, single-arm, open-label PRIMARY OBJECTIVE The primary objective is to assess safety of the UNITY Balloon-expandable Biodegradable Biliary Stent System SECONDARY OBJECTIVES Clinical /Technical /Procedural success, Quality of Life improvement, biodegradation rate

NCT ID: NCT04929210 Recruiting - Clinical trials for Arthritis, Psoriatic

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

STAR
Start date: August 30, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

NCT ID: NCT04919265 Recruiting - Asthma Clinical Trials

Mother-Infant Cohort Study in Malaysia and China

Start date: June 3, 2022
Phase:
Study type: Observational

This mother-infant cohort study aims to determine the geographic differences in the microbial profiles in breast milk from mothers living in Malaysia and China that are potentially important determinants of infant development. It also aims to determine the impact of gut microbiome on infant health (temperament, gastrointestinal symptoms, eczema symptoms, and asthma symptoms).

NCT ID: NCT04919044 Recruiting - Old Age; Debility Clinical Trials

Motor Imagery Training in Community Dwelling Elderly

Start date: August 8, 2021
Phase: N/A
Study type: Interventional

An aging society is known as having at least 7% of its population aged 65 and older, whereas 14% or more known to be an aged nation. Age has a detrimental effect on the physical performance and the muscle strength, the reduced muscle strength, mass and structure in the elderly are due to aging, disuse and inactivity. In the elderly, the reduction of muscle strength is faster than the associated loss of muscle mass. The maximum isometric strength of knee extensors and muscle mass decrease due to aging. The combination of quadriceps and handgrip strength weakness in the elderly is associated with the poorest scores on quality of life, GP contact-time, gait speed, hospitalization and disability in daily living. Quadriceps weakness among elderly is also proved to be a contributing factor to fall among frail nursing home residents. A systematic review and meta-analysis revealed that quadriceps muscle weakness was associated with greater risk of developing knee osteoarthritis during 2.5 to 14 year follow-up in either gender. In overall, aging cause reduce muscle strength, especially quadriceps muscle, can cause many others negative consequences, thus a study of effect motor imagery on quadriceps muscle strength in community-dwelling elderly should be carried out, if this study is proven to effectively, motor imagery technique can be widely utilized on bedridden elderly or elderly who have severe cardiovascular disease who unable to perform physical activity to maintain or improve their muscle strength.

NCT ID: NCT04918017 Recruiting - Clinical trials for Functional Dyspepsia

Treatment Outcomes For Functional Dyspepsia Based On Current International Guidelines In Multi-Ethnic Asian Patients

Start date: November 18, 2021
Phase: Phase 4
Study type: Interventional

Functional dyspepsia (FD) is among the most established and common functional gastrointestinal disorders (FGIDs). FD is subdivided into two subtypes based on symptoms: epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS). Based on international guidelines (Asian Consensus and Rome Consensus), a prokinetic, medication which promotes gut movement (such as Itopride) should be the 1st line treatment for the PDS sub-type and a proton pump inhibitor, medication which reduces stomach acid production (such as Esomeprazole) should be the 1st line treatment for the EPS sub-type. However, in the routine practice in Malaysia, proton pump inhibitor is still commonly used as 1st line treatment for FD, regardless of subtypes. This may be one of the reasons why FD continues to be inadequately treated locally and causes poor health-related quality of life (QOL) in FD patients. The purpose of this study is to compare the clinical symptoms and quality of life improvement in patients with functional dyspepsia (FD) after treatment according to international guidelines versus treatment according to routine practice. Adverse effects when managed according to guidelines versus routine practice will also be evaluated.